Education
About Us
Working with TipRanks
Follow Us
Pacific Biosciences (PACB)
NASDAQ:PACB
Earnings Data
Report Date
May 06, 2026TBA (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.15Last Year’s EPS
-1.44Same Quarter Last Year
Moderate Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call highlighted meaningful operational improvements: record consumable performance, strong consumable-driven gross margin expansion to 40%, cost reductions and improved cash burn, promising SparkNex beta results (25% higher throughput and sub-$300 genome target), and accelerating clinical/population sequencing traction. Offsetting these positives are persistent full-year net losses, a decline in instrument revenue driven by a weak academic funding environment (particularly in the Americas), lower unrestricted cash versus prior year, ASP and discount dynamics from strategic placements, and supply-cost volatility (compute/memory) that could temper margin gains. Management provided modest 2026 guidance (~8% growth at midpoint) that assumes continued academic caution but expects SparkNex and clinical adoption to accelerate growth. Overall, the company appears to be making solid progress operationally and strategically while still managing execution and market-demand risks.Company Guidance
Quarterly and Sequential Revenue Growth
Q4 2025 revenue of $44.6M, up 14% year-over-year and 16% quarter-over-quarter, driven by increased Revio and Vega sales and record consumables.
Record Consumables Performance
Consumables reached another record in Q4 with revenue of $21.6M (Q4 consumables +15% YoY). Full-year consumables were $82M, up 16% YoY, and consumable shipments grew 19% in 2025. Clinical & hospital consumables grew 55% in 2025.
Improved Gross Margins
Non-GAAP gross margin improved to 40% in Q4 and full-year 2025 (from 31% Q4 2024 and 33% full-year 2024). Management cites a 1,300 basis point improvement since 2023 and a 700 basis point improvement in 2025 alone.
Instrument Placements and Platform Momentum
Q4 shipments included 21 Revio and 42 Vega systems, bringing cumulative shipments to 331 Revio and 147 Vega systems. Vega showed strong order trends, with ~65% of 2025 Vega placements to new-to-PacBio customers, expanding HiFi adoption.
SparkNex Chemistry and Multi-use SMRT Cell Progress
SparkNex beta results reported 25% higher output per SMRT Cell and higher yields/read quality vs prior chemistry. Company targets whole-genome HiFi sequencing at scale for under $300 per genome and plans broader launch in 2026.
Clinical and Population Sequencing Traction
Notable clinical initiatives (University of Washington, Ambry ONCE study enrolling ~1,000 in 2026, IHOPE inclusion, Babies in Focus) and large population projects (All of Us publication, Long Life Family Study, Asian Pan-Genome) demonstrating adoption and pipeline.
Operating Expense and Cash Burn Improvements
Non-GAAP operating expenses reduced to $229.9M in 2025 (from $289.2M in 2024; 20% YoY reduction). Cash burn (ex-financings/acquisitions) improved from $214M in 2023 to $105M in 2025 (51% improvement since 2023; 44% YoY).
Balance Sheet Strengthening
Sale of short-read sequencing assets produced ~ $48M net proceeds and the company ended 2025 with approximately $279.5M in unrestricted cash, cash equivalents, and investments, extending runway and focusing resources on long-read strategy.
PACB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
PACB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 12, 2026 | $1.84 | $1.71 | -7.07% |
Nov 05, 2025 | $1.92 | $1.78 | -7.05% |
Aug 07, 2025 | $1.26 | $1.35 | +7.14% |
May 08, 2025 | $1.20 | $1.12 | -6.67% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Pacific Biosciences (PACB) report earnings?
Pacific Biosciences (PACB) is schdueled to report earning on May 06, 2026, TBA (Confirmed).
What is Pacific Biosciences (PACB) earnings time?
Pacific Biosciences (PACB) earnings time is at May 06, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PACB EPS forecast?
PACB EPS forecast for the fiscal quarter 2026 (Q1) is -0.15.